Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): The prospective international multicentre phase 2 PTLD-1 trial

The Lancet Oncology

Volumn 13, Issue 2, 2012, Pages 196-206

  Trappe, Ralf ^a,b   Oertel, Stephan ^c   Leblond, Veronique ^d   Mollee, Peter ^e   Sender, Monica ^f   Reinke, Petra ^a   Neuhaus, Ruth ^a   Lehmkuhl, Hans ^g   Horst, Heinz August ^b   Salles, Gilles ^h   Morschhauser, Franck ⁱ   Jaccard, Arnaud ^j   Lamy, Thierry ^k   Leithäuser, Malte ^l   Zimmermann, Heiner ^b   Anagnostopoulos, Ioannis ^a   Raphael, Martine ^m   Riess, Hanno ^a   Choquet, Sylvain ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e PRINCESS ALEXANDRA HOSPITAL   (Australia)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^h CENTRE HOSPITALIER LYON SUD   (France)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j LIMOGES UNIVERSITY HOSPITAL   (France)

^k RENNES UNIVERSITY HOSPITAL   (France)

^l UNIVERSITY OF ROSTOCK   (Germany)

^m BICÊTRE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; BILIARY TRACT HEMORRHAGE; BLEEDING; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS INFECTION; FEMALE; HEART TRANSPLANTATION; HEPATITIS C REACTIVATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER TRANSPLANTATION; LUNG HEMORRHAGE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SCHWARTZ BARTTER SYNDROME; SEPSIS; SIDE EFFECT; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FRANCE; GERMANY; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PREDNISOLONE; PROSPECTIVE STUDIES; VINCRISTINE;

EID: 84856412562     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70300-X     Document Type: Article

References (35)

1. Penn I, Hammond W, Brettschneider L, Starzl TE Malignant lymphomas in transplantation patients. Transplant Proc 1969, 1:106-112.
2. Swerdlow SH, Webber SA, Chadburn A, Ferry JA Post-transplant lymphoproliferative disorders. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, 343-350. IARC, Lyon. 4th edn. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
3. Nelson BP, Nalesnik MA, Bahler DW, Locker J, Fung JJ, Swerdlow SH Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?. Am J Surg Pathol 2000, 24:375-385.
4. Leblond V, Davi F, Charlotte F, et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?. J Clin Oncol 1998, 16:2052-2059.
5. Smets F, Latinne D, Bazin H, et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 2002, 73:1603-1610.
6. Wagner HJ, Wessel M, Jabs W, et al. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation 2001, 72:1012-1019.
7. Quinlan SC, Morton LM, Pfeiffer RM, et al. Increased risk for lymphoid and myeloid neoplasms in elderly solid-organ transplant recipients. Cancer Epidemiol Biomarkers Prev 2010, 19:1229-1237.
8. Reshef R, Vardhanabhuti S, Luskin MR, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder. Am J Transplant 2011, 11:336-347.
9. Trappe R, Zimmermann H, Fink S, et al. Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease-a prospective analysis of 8 cases. Haematologica 2011, 96:1067-1071.
10. Swinnen LJ, LeBlanc M, Grogan TM, et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation 2008, 86:215-222.
11. Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005, 5:2901-2906.
12. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicentre phase II study. Blood 2006, 107:3053-3057.
13. Gonzalez-Barca E, Domingo-Domenech E, Capote FJ, et al. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica 2007, 92:1489-1494.
14. Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010, 28:1038-1046.
15. Choquet S, Oertel S, LeBlond V, et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol 2007, 86:599-607.
16. Choquet S, Trappe R, Leblond V, Jäger U, Davi F, Oertel S CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 2007, 92:273-274.
17. Garrett TJ, Chadburn A, Barr ML, et al. Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy. Cancer 1993, 72:2782-2785.
18. Mamzer-Bruneel MF, Lome C, Morelon E, et al. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: a report of 16 cases observed in a single center. J Clin Oncol 2000, 18:3622-3632.
19. Norin S, Kimby E, Ericzon BG, et al. Posttransplant lymphoma-a single-center experience of 500 liver transplantations. Med Oncol 2004, 21:273-284.
20. Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006, 6:569-576.
21. Fohrer C, Caillard S, Koumarianou A, et al. Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen. Br J Haematol 2006, 134:602-612.
22. Taylor AL, Bowles KM, Callaghan CJ, et al. Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation. Transplantation 2006, 82:375-381.
23. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues 2001, IARC Press, Lyon. E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (Eds.).
24. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005, 106:1538-1543.
25. Miller AB, Hoogstraten B, Staquet M, Winkler A Reporting results of cancer treatment. Cancer 1981, 47:207-214.
26. Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer 2005, 104:1661-1667.
27. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007, 110:1123-1131.
28. Parker A, Bowles K, Bradley JA, et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients-BCSH and BTS Guidelines. Br J Haematol 2010, 149:693-705.
29. Dayde D, Ternant D, Ohresser M, et al. Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood 2009, 113:3765-3772.
30. Ternant D, Henin E, Cartron G, Tod M, Paintaud G, Girard P Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma. Br J Clin Pharmacol 2009, 68:561-573.
31. Trappe R, Hinrichs C, Appel U, et al. Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression. Am J Transplant 2009, 9:2331-2337.
32. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998, 92:1927-1932.
33. Dojcinov SD, Venkataraman G, Pittaluga S, et al. Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood 2011, 117:4726-4735.
34. Cartron G, Trappe RU, Solal-Celigny P, Hallek M Interindividual variability of response to rituximab: from biological origins to individualized therapies. Clin Cancer Res 2011, 17:19-30.
35. Trappe R, Choquet S, Oertel SHK, et al. Sequential treatment with rituximab and CHOP chemotherapy in B-Cell PTLD-moving forward to a first standard of care: results from a prospective international multicenter trial. Blood 2009, 114. abstr 100.